公开(公告)号：US11466048B2

公开(公告)日：2022-10-11

申请号：US16802014

申请日：2020-02-26

Applicant: NOVARTIS AG

Inventor： David Barnes-Seeman ,  Scott Louis Cohen ,  John Louis Diener ,  Christian Gampe ,  James Roache ,  Amy White ,  Sarah Louise Williams ,  Jun Yuan ,  Frederic Zecri

IPC: C07H21/02 ,  C07F9/6561 ,  C07H19/167 ,  C07H19/207 ,  C07K14/575

Abstract: The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

公开(公告)号：US10676499B2

公开(公告)日：2020-06-09

申请号：US15536516

申请日：2015-12-16

Applicant: NOVARTIS AG

Inventor： David Barnes-Seeman ,  Scott Louis Cohen ,  John Louis Diener ,  Christian Gampe ,  James Roache ,  Amy White ,  Sarah Williams ,  Jun Yuan ,  Frederic Zecri

IPC: C07H21/02 ,  C07F9/6561 ,  C07H19/167 ,  C07H19/207 ,  C07K14/575

Abstract: The disclosure relates to nucleic acids that contain modifications at the 5′-end, 3′-end or 5′-end and 3′-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.

公开(公告)号：US11963999B2

公开(公告)日：2024-04-23

申请号：US16407813

申请日：2019-05-09

Applicant: Novartis AG

Inventor： John Louis Diener ,  Jiaping Gao ,  Rick Jerome Schiebinger

IPC: A61K38/18 ,  C07K14/50

CPC classification number: A61K38/1825 ,  C07K14/50 ,  C07K2319/30

Abstract: The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and/or autoimmune insulin receptor disorders (Type B insulin Resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and other metabolic disorders, and various lipodystrophies such as HIV-HAART induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients.

公开(公告)号：US11066469B2

公开(公告)日：2021-07-20

申请号：US16897935

申请日：2020-06-10

Applicant: NOVARTIS AG

Inventor： John Louis Diener ,  Lars Gadtke ,  Felix Hartlepp ,  Kathrin Ladetzki-Baehs ,  Michael Romanowski ,  Cesare Russo ,  Xenia Wezler

IPC: C07K16/28 ,  A61K39/395 ,  A61P9/00 ,  A61P13/12 ,  C07K14/72 ,  A61K45/06 ,  A61K39/00 ,  C07K14/58

Abstract: This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.